TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26023778
Drug: Two dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose booster regimen of OCV (n = 184)
Study: 26023778
Drug: Single boosting
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single boosting dose of OCV
Study: 26023778
Drug: Two dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose primary series of OCV (n = 186)
Study: 21640866
Drug: 1% casein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) solution
Study: 16708532
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg slow release)
Study: 15270791
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of questionnaire and FPG
Study: 9550641
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg o.d. (slow release formulation) for 1 week
Study: 2903386
Drug: Oral co‐trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co‐trimoxazole for 5 days
Study: 2903386
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular dose of fortified procaine penicillin and 5 days of oral ampicillin
Study: 19572180
Drug: Both 585
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 585 nm and 595 nm PDL treatments
Study: 10895201
Drug: Doxorubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50 mg/m2 IV bolus) followed one hour later by Taxotere (60 mg/m2 IV infusion over 1 hour every 3 weeks for 6 cycles)
Study: 8831596
Drug: Intravenous cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefotaxime
Study: 1578593
Drug: Buprenorphine, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine, 8 mg/d
Study: 1578593
Drug: Methadone, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone, 60 mg/d
Study: 1578593
Drug: Methadone, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone, 20 mg/d
Study: 28451529
Drug: Strengthened self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthened self-management program guidance (including seven modules: disease knowledge, breathing exercises, emotion management, home oxygen therapy, medicine intake technique, healthy life behaviors, action plans in deterioration stage)
Study: 17242627
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 or 6 mg depending on body weight)
Study: 11736864
Drug: Six drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, chlorzoxazone 250 mg, diclofenac 25 mg, MDZ 5 mg)
Study: 11736864
Drug: Five drug
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, diclofenac 50 mg, without chlorzoxazone)
Study: 11736864
Drug: Six drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six drug cocktail (as above with chlorzoxazone)
Study: 9431858
Drug: Lacidipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (2 mg once daily)
Study: 9431858
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg once daily)
Study: 8305770
Drug: Mylan's MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mylan's MTX tablets (15 mg administered as six 2.5-mg tablets)
Study: 8305770
Drug: Lederle's MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle's MTX tablets (15 mg administered as six 2.5-mg tablets)
Study: 3790405
Drug: Anticholinergic drugs
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drugs (Atropine and Glycopyrrolate)
Study: 31574025
Drug: Bleomycin injection
Normalized name: bleomycin Injection
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bleomycin injection
Study: 23530962
Drug: Full mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full mouth periodontal treatment with an ultrasonic device and supragingival plaque control
Study: 21784145
Drug: n-3 supplementation
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 supplementation (2.5 g/d, 2085 mg eicosapentaenoic acid and 348 mg docosahexanoic acid)
Study: 16751617
Drug: Hypertonic-hyperoncotic solution
Normalized name: Hypertonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic-hyperoncotic solution (Poly-(O-2)-hydroxyethyl-starch 60.0 g, Na+ 1232 mmol/L, osmolality 2464 mOsmol/L)
Study: 16758849
Drug: Hypertonic-hyperoncotic solution
Normalized name: Hypertonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic-hyperoncotic solution
Study: 16751617
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution (0.9% sodium chloride)
Study: 11220717
Drug: Omeprazole therapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole therapy (40 or 60 mg daily as needed)
Study: 7931474
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A (100,000 IU/d) for 18 months
Study: 3229297
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg L-acetylcarnitine
Study: 3229297
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg L-acetylcarnitine
Study: 3229297
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg L-acetylcarnitine
Study: 21982758
Drug: 1 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L/min O(2) via a demand system during sleep (n = 3)
Study: 21982758
Drug: 1 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L/min O(2)/CO(2) mix (1.5% CO(2)) via a demand system during sleep (n = 4)
Study: 21982758
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg acetazolamide 30 minutes before bedtime (n = 4)
Study: 18781275
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 5 mg/kg over 24 h
Study: 12854104
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (standard peripheral intravenous nutrition with heparin and hydrocortisone plus topical GTN)
Study: 12854104
Drug: Monotherapy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (standard peripheral intravenous nutrition with topical GTN only)
Study: 12854104
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (standard peripheral intravenous nutrition with heparin and hydrocortisone plus topical GTN)
Study: 6103299
Drug: Oral diethylcarbamazine
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral diethylcarbamazine citrate (DEC)
Study: 7020746
Drug: Topical diethylcarbamazine
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical diethylcarbamazine (DEC) lotion
Study: 6103299
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and topical DEC)
Study: 31820059
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin (30 International Units Insulin Regular in 30 ml of normal saline)
Study: 25459392
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) at a dosage of 1.000mg/m² d1, 8, 15 q28
Study: 21959870
Drug: Epoetin-β (EPO)
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-β (EPO) 36,000 IU weekly for 12 weeks
Study: 11102251
Drug: Lanoteplase 120
Normalized name: Lanoteplase
DrugBank: Lanoteplase (DB06245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoteplase 120 KU/kg as a single intravenous bolus
Study: 11102251
Drug: Accelerated alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated alteplase up to 100 mg given over 90 min
Study: 9470884
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patch (24 hour transdermal nicotine patch over a 10 week course)
Study: 7958544
Drug: Monomeric insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monomeric insulin analogue [Lys(B28),Pro(B29)] (MI)
Study: 2884796
Drug: atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.5 mg X kg‐1
Study: 2884796
Drug: pipecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: pipecuronium 0.1 mg X kg‐1
Study: 2884796
Drug: vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.1 mg X kg‐1
Study: 26563915
Drug: Vitamin D-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-containing supplements ≥3 days/week
Study: 12627405
Drug: Proposed treatment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed treatment method based on joint toxicity and efficacy
Study: 19458926
Drug: Baclofen 60
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 60 mg/day
Study: 22540412
Drug: Platform-switched implants
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implants (mismatch 0.35-0.40 mm)
Study: 22540412
Drug: Conventional implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implants (control)
Study: 20730060
Drug: Valsartan 40
Normalized name: valsartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 40 mg bid (n = 60)
Study: 20730060
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg qd (n = 55)
Study: 20730060
Drug: Valsartan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (both dosing regimens)
Study: 16183682
Drug: bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.125% with fentanyl 3 microg ml(‐1)
Study: 16183682
Drug: bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.125% with clonidine 0.6 microg ml(‐1)
Study: 12861131
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (5 mg/d for 13 days every 3 months)
Study: 1387806
Drug: Initial empirical
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial empirical regimen with antibiotics active against gram-positive organisms
Study: 30113522
Drug: whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: whey protein (25 g) plus HMB (1.5 g)
Study: 30113522
Drug: whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: whey protein (25 g) plus leucine (1.5 g)
Study: 24584876
Drug: Standard doxorubicin-cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doxorubicin-cyclophosphamide followed by paclitaxel with bevacizumab therapy (duration not specified)
Study: 22965699
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine combined with Chinese medicine (CM) treatment
Study: 22965699
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Amlodipine Besylate Tablets and Irbesartan Tablets or Irbesartan and Hydrochlorothiazide Tablets)
Study: 18845709
Drug: Single PS
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single PS dose consumed as an afternoon snack (1.6 g/d)
Study: 18845709
Drug: Single PS
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single PS dose consumed with a meal (1.6 g/d)
Study: 18845709
Drug: Single PS
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single PS dose consumed as an afternoon snack
Study: 18845709
Drug: Single PS
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single PS dose consumed with a meal
Study: 16150741
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention (diagnostic and treatment algorithm, small group sessions, videotapes, written material, outreach visits, one-on-one interviews with physicians)
Study: 10202165
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m² per week for six weeks (group 1)
Study: 10202165
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m² on days 1 and 29, 4 g of fluorouracil per m² as a 96-hour infusion on days 1 and 29, and 2 g of oral hydroxyurea twice weekly for six weeks (group 2)
Study: 10202165
Drug: Hydroxyurea 3
Normalized name: hydroxyurea 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea 3 g/m² twice weekly for six weeks (group 3)
Study: 7869476
Drug: Indoramin (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (alpha 1‐adrenergic receptor antagonist)
Study: 2611090
Drug: Aspirin 1.95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1.95 g day‐1 for 1 week
Study: 2611090
Drug: Aspirin 3.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 3.25 g day‐1 for 1 week
Study: 2611090
Drug: Aspirin 4.55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 4.55 g day‐1 for 1 week
Study: 2611090
Drug: Aspirin 5.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 5.85 g day‐1 for 1 week
Study: 25451428
Drug: Psychoeducational family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational family intervention (PFI) and Treatment As Usual (TAU)
Study: 23553151
Drug: Flavonoid-enriched chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-enriched chocolate (27 g/d; 850 mg flavan-3-ols + 100 mg isoflavones)
Study: 22162988
Drug: Strategy A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy A (two standard doses over 28 days)
Study: 22162988
Drug: Strategy B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy B (two double doses over 28 days)
Study: 22162988
Drug: Strategy C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy C (single standard dose of influenza vaccine)
Study: 22162988
Drug: Strategy D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy D (previous year's standard-dose vaccination)
Study: 18085694
Drug: Azithromycin 10
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 10 mg/kg/day
Study: 16282339
Drug: Acyclovir 800
Normalized name: acyclovir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 800 mg twice daily
Study: 10922130
Drug: Prednisolone 1
Normalized name: prednisolone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1 mg/kg/day for 7 days
Study: 1329618
Drug: Rufloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin 400 mg loading dose followed by 200 mg daily for 9 days
Study: 1329618
Drug: Rufloxacin 600
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rufloxacin 600 mg loading dose followed by 300 mg daily for 9 days
Study: 4019262
Drug: Riboflavin plus
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin plus iron supplements
Study: 17965424
Drug: etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 90 mg daily
Study: 17965424
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg twice daily
Study: 16195291
Drug: Various interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various interventions for treatment (35 trials)
Study: 7674172
Drug: Heparin-surface-modified lens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified lens
Study: 2403065
Drug: Caffeine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (400 mg/d)
Study: 7223262
Drug: Cefamandole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (3 x 2 g I.V. within 24 hrs, first dose at anesthetic induction)
Study: 7223262
Drug: Clindamycin-Tobramycin (clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin-Tobramycin (clindamycin 600 mg - tobramycin 80 mg/8 hrs for 24 hrs, first dose at anesthetic induction)
Study: 31293021
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa (2 g/day)
Study: 23955585
Drug: Control arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arms (standard chemotherapy)
Study: 23955585
Drug: Experimental arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arms (intensified chemotherapy)
Study: 19446622
Drug: PHFST 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHFST 240 mg single dose
Study: 19446622
Drug: PHFST 180-210
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHFST 180-210 mg single dose
Study: 19446622
Drug: PHFST 30-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHFST 30-150 mg single dose
Study: 19446622
Drug: PHFST multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHFST multiple dosing (60 mg b.i.d. up to 120 mg b.i.d.)
Study: 8562752
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of azithromycin orally (single dose)
Study: 8562752
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of ceftriaxone im (single dose)
Study: 24161420
Drug: Accelerated Partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Partial Breast Irradiation (APBI) - 37.5 Gy in 3.75 Gy per fraction delivered twice daily
Study: 24161420
Drug: Whole Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Breast Irradiation (WBI) - 48 Gy delivered in daily fractions of 2 Gy, with or without additional 10 Gy to the tumor bed
Study: 19733721
Drug: Naproxcinod 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxcinod 750 mg
Study: 11741526
Drug: Treatment (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (specific treatment not mentioned)
Study: 9505912
Drug: Abciximab added
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab added to intravenous heparin and aspirin regimen
Study: 2543246
Drug: Max‐EPA (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max‐EPA (3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid)
Study: 4969551
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg t.d.s.
Study: 4969551
Drug: Verapamil 40
Normalized name: verapamil 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 40 mg t.d.s.
Study: 4969551
Drug: Propranolol 100
Normalized name: propranolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 100 mg t.d.s.
Study: 25605841
Drug: Rituximab re-treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab re-treatment (RR)
Study: 8271292
Drug: Fenretinide 200
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide 200 mg daily for a median of 32 months
Study: 2929705
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear formulation (solution 15 with demulcent and buffering system, osmolarity 162 mOsm/l)
Study: 20367667
Drug: 24 mg/mL
Normalized name: sulfur 24 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg/mL hyaluronic acid with pre-incorporated 0.3% lidocaine
Study: 18397977
Drug: 6-month thyroid
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month thyroid hormone substitution regimen to obtain euthyroidism
Study: 9803985
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral tablet dose of 20 mg temocapril hydrochloride
Study: 9803985
Drug: Seven once
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven once daily oral tablet doses of 20 mg temocapril hydrochloride
Study: 19846281
Drug: Lorazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2.5 mg single dose)
Study: 15016255
Drug: Written information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written information provided prior to treatment
Study: 7932194
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day lovastatin
Study: 2676654
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day lovastatin
Study: 7932194
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day lovastatin
Study: 7932194
Drug: 0 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/day lovastatin (baseline)
Study: 27175685
Drug: Dexmedetomidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.3 μg/kg/hour continuous infusion)
Study: 20187094
Drug: Intra-arterial (IA)
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial (IA) chemoradiation with 4x150 mg/m(2) cisplatin administered in the tumor-feeding artery on Days 1, 8, 15, 22, followed by sodium thiosulfate and 70 Gy in 35 daily fractions.
Study: 20187094
Drug: Intravenous chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemoradiation with 3x100 mg/m(2) cisplatin infusion on Days 1, 22, 43 and 70 Gy in 35 daily fractions.